Court's 'Pay-to-Delay' Ruling Met With Criticism

A Supreme Court decision allowing federal regulators to continue challenging "pay-for-delay" deals between pharmaceutical companies and generic drug makers on anti-competitive grounds was greeted with dismay by industry observers after the court failed to rule whether such arrangements are legal.